CAR-T Meeting 2024 | The potential biomarkers of interest in immune effector cell-associated HLH following CAR-T
Edoardo Campodonico, MD, IRCCS San Raffaele Scientific Institute, Milan, Italy, discusses an investigation into the biomarkers of interest in immune effector cell-associated hemophagocytic lymphohistiocytosis (HLH), a potential adverse event following CAR T-cell infusion. Specific biomarkers were compared between patients who did and did not develop HLH to try to discriminate this entity from other types of acute inflammatory toxicities. Clinical predictive factors for post-CAR HLH include tumor burden and prior comorbidities. However, Dr Campodonico highlights that serum biomarkers are still poorly understood and would allow for early identification and treatment to improve outcomes of patients with this complication. This interview took place at the EBMT-EHA 6th European CAR T-cell Meeting in Valencia, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
